Feb 10, 2020 8:30am EST Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
Dec 18, 2019 3:00pm EST Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
Jul 24, 2019 9:25am EDT Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
Jan 07, 2019 8:39am EST Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
